ClinConnect ClinConnect Logo
Search / Trial NCT01721278

Furlong Evolution® Hip Trial

Launched by IMPERIAL COLLEGE LONDON · Nov 1, 2012

Trial Information

Current as of June 02, 2025

Unknown status

Keywords

ClinConnect Summary

Purpose and Design:

The Furlong Evolution® design is based on the tried and tested Furlong H.A.C implant but with some modifications. It still retains its full H.A.C coating and is much shorter in length. This potentially makes it easier to introduce into the femoral canal, which may result in less soft tissue damage and lower rate of femoral fracture. This would be very beneficial, should revision (implant replacement) be required at a later date. This potential characteristic has been highlighted as an important component of determining the clinical effectiveness of a total hip replaceme...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. All patients consenting to total hip replacement
  • 2. All patients deemed suitable for total hip replacement
  • 3. All patients passing pre-assessment deeming them medically fit enough for total hip replacement.
  • Exclusion Criteria:
  • 1. Patients deemed unsuitable for Total Hip Replacement
  • 2. Patients who refuse to have surgery opting for other modes of treatment
  • 3. Patients who are unable to consent due to a lack of capacity
  • 4. Patients unable to understand English
  • 5. Any patient under the age of 18 years.
  • 6. Patients who are pregnant or breast feeding

About Imperial College London

Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Professor Justin Cobb, MCh FRCS

Principal Investigator

Imperial College London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials